239 related articles for article (PubMed ID: 30068244)
61. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
Gaballa S; Saliba R; Oran B; Brammer JE; Chen J; Rondon G; Alousi AM; Kebriaei P; Marin D; Popat UR; Andersson BS; Shpall EJ; Jabbour E; Daver N; Andreeff M; Ravandi F; Cortes J; Patel K; Champlin RE; Ciurea SO
Am J Hematol; 2017 Apr; 92(4):331-337. PubMed ID: 28052408
[TBL] [Abstract][Full Text] [Related]
62. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
63. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
64. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
Shayegi N; Kramer M; Bornhäuser M; Schaich M; Schetelig J; Platzbecker U; Röllig C; Heiderich C; Landt O; Ehninger G; Thiede C;
Blood; 2013 Jul; 122(1):83-92. PubMed ID: 23656730
[TBL] [Abstract][Full Text] [Related]
65. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A; Oñate G; Diaz-Beyá M; Guijarro F; Garrido A; Vives S; Tormo M; Arnan M; Salamero O; Sampol A; Coll R; Vall-Llovera F; Oliver-Caldés A; López-Guerra M; Pratcorona M; Zamora L; Villamon E; Roué G; Blanco A; Nomdedeu JF; Colomer D; Brunet S; Sierra J; Esteve J;
Br J Haematol; 2020 Oct; 191(1):52-61. PubMed ID: 32510599
[TBL] [Abstract][Full Text] [Related]
66. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
[TBL] [Abstract][Full Text] [Related]
67. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U; Haferlach T; Fehse B; Schnittger S; Kröger N
ScientificWorldJournal; 2011 Feb; 11():310-9. PubMed ID: 21298222
[TBL] [Abstract][Full Text] [Related]
68. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
69. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
[TBL] [Abstract][Full Text] [Related]
70. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
71. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
[TBL] [Abstract][Full Text] [Related]
72. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
73. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
74. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
75. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
76. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
77. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
78. MRD evaluation of AML in clinical practice: are we there yet?
Freeman SD; Hourigan CS
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):557-569. PubMed ID: 31808906
[TBL] [Abstract][Full Text] [Related]
79. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M; Derkach A; Farnoud N; Bewersdorf JP; Robinson T; Famulare C; Cho C; Devlin S; Menghrajani K; Patel MA; Cai SF; Miles LA; Bowman RL; Geyer MB; Dunbar A; Epstein-Peterson ZD; McGovern E; Schulman J; Glass JL; Taylor J; Viny AD; Stein EM; Getta B; Arcila ME; Gao Q; Barker J; Shaffer BC; Papadopoulos EB; Gyurkocza B; Perales MA; Abdel-Wahab O; Levine RL; Giralt SA; Zhang Y; Xiao W; Pai N; Papaemmanuil E; Tallman MS; Roshal M; Goldberg AD
Am J Hematol; 2023 Jan; 98(1):79-89. PubMed ID: 36251406
[TBL] [Abstract][Full Text] [Related]
80. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
